Geneuro Logo

Geneuro

GEM | PA

Overview

Corporate Details

ISIN(s):
CH0308403085
LEI:
213800FUJCKXO9LK3444
Country:
Switzerland
Address:
chemin du Pré-Fleuri 3, 1228 Plan-les-Ouates
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

GeNeuro is a Swiss-based, clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative and autoimmune diseases. The company utilizes a novel therapeutic approach that targets pathogenic proteins encoded by human endogenous retroviruses (HERVs), which are believed to contribute to the progression of diseases such as Multiple Sclerosis (MS), Amyotrophic Lateral Sclerosis (ALS), and post-COVID conditions. Its main drug candidate, temelimab, is being developed to treat the cognitive and fatigue symptoms associated with Long COVID. In July 2024, the company was granted a debt-restructuring moratorium.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Geneuro. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-30 19:37
Post-Annual General Meeting Information
Inside Information / Other news releases
English 224.5 KB
2025-06-30 19:37
Post-Annual General Meeting Information
Informations privilégiées / Autres communiqués
French 753.1 KB
2025-06-12 22:42
Legal Proceedings Report
Inside Information / Other news releases
English 204.9 KB
2025-06-12 22:42
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 203.8 KB
2025-06-10 18:24
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 207.4 KB
2025-06-10 18:24
Pre-Annual General Meeting Information
Inside Information / Other news releases
English 209.5 KB
2025-05-27 18:00
Legal Proceedings Report
Inside Information / Other news releases
English 162.5 KB
2025-05-27 18:00
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 187.1 KB
2025-05-12 18:36
Report Publication Announcement
Inside Information / Other news releases
English 481.8 KB
2025-05-12 18:36
Report Publication Announcement
Informations privilégiées / Autres communiqués
French 669.5 KB

Automate Your Workflow. Get a real-time feed of all Geneuro filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Geneuro via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
NextGen Biomed Ltd. Logo
R&D of biotech medical devices for diabetes care and topical skin treatments.
Israel NXGN
NFL Biosciences Logo
Develops botanical drug candidates to treat smoking and alcohol addictions for pharma licensing.
France ALNFL
Nicox S.A. Logo
Developing innovative ophthalmology drugs for glaucoma and ocular hypertension.
France COX
Nortem BioGroup Logo
Biotech R&D of natural products for consumer health, home, and animal nutrition.
Spain MLBIO
NRGene Technologies Ltd. Logo
AI genomics software accelerating plant & animal breeding for the agriculture industry.
Israel NRGN
NUFORMIX PLC Logo
A pharma firm repurposing drugs for fibrosis and oncology via proprietary cocrystal technology.
United Kingdom NFX
Nykode Therapeutics ASA Logo
Developing targeted immunotherapies and vaccines for cancer and infectious diseases.
Norway NYKD
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive drugs for sight-threatening eye diseases.
Switzerland OCS
ONCIMMUNE HOLDINGS PLC Logo
Antibody biomarker discovery platform for pharma and biotech partners in oncology and autoimmune disease.
United Kingdom ONC
ONCODESIGN Logo
Develops precision cancer therapies and diagnostics targeting resistance and metastasis.
France ALONC